NCT05388903View on ClinicalTrials.gov

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

January 26, 2023

Study Completion Date

January 26, 2023

Conditions
Netherton Syndrome
Interventions
DRUG

DS-2325a

Subcutaneous injection (starting dose 30 mg)

DRUG

DS-2325a

Intravenous infusion (starting dose 100 mg)

DRUG

Placebo

Subcutaneous injection

DRUG

Placebo

Intravenous infusion

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT05388903 - A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects | Biotech Hunter | Biotech Hunter